SUPPLEMENTARY MATERIAL

Supplemental Table 1. Baseline characteristics of the participants taking part either in the short-term, long-term or both follow-ups.

Baseline population consists of the following subpopulations:

- 54 participants, who were premenopausal at ERMA baseline and were re-measured only at long-term follow-up.
- 230 participants, who were perimenopausal at ERMA baseline and completed the short-term follow-up.
- 32 participants, who were perimenopausal at ERMA baseline and were re-measured only at long-term follow-up.

	All $(n=316)$	Premenopausal $(n = 54)$	Perimenopausal $(n = 262)$
Age and systemic hormones	,		
Age, y	51.4 ± 1.9	51.0 ± 1.7	51.5 ± 1.9*
E ₂ , nmol/L	0.40 ± 0.40	0.70 ± 0.71	0.33 ± 0.27***
FSH, IU/L	30.2 ± 22.2	7.9 ± 3.7	34.8 ± 21.6***
DHEAS, µmol/l ^a	2.73 ± 1.40	2.49 ± 1.48	2.77 ± 1.38
SHBG, nmol/l ^a	56.4 ± 24.3	60.7 ± 32.0	55.5 ± 22.4
Demographics			
Education level ^a			
Primary	2.2%	0.0%	2.7%
Secondary	51.7%	55.6%	51.0%
Tertiary	46.0%	44.4%	46.4%
Bleeding status			
Natural	59.5%	35.2%	64.5%***
IUD	33.9%	50.0%	30.5%
Hysterectomy	6.6%	14.8%	5.0%
Lifestyle habits			
SR-PA, MET-h/day b	4.67 ± 4.07	4.79 ± 3.80	4.64 ± 4.12
ACC-PA, min/day c	53.6 ± 30.3	53.5 ± 27.1	53.6 ± 31.0
Diet quality score d	5.84 ± 2.32	5.27 ± 2.72	5.95 ± 2.22*
Smoking			
Never	69.6%	74.1%	68.7%
Quitter	23.7%	20.4%	24.4%
Current smoker	6.6%	5.6%	6.9%
Alcohol use, units/week e	4.0 ± 3.6	3.7 ± 3.1	4.1 ± 3.7

Values are presented as mean \pm SD. E2, estradiol; FSH, follicle-stimulating hormone; DHEAS, dehydroepiandrosterone sulfate; SHBG, sex hormone binding globulin; IUD, intrauterine device (includes also other progestogenic contraception preparations); SR-PA, self-reported physical activity; MET, metabolic equivalent of a task; ACC-PA, accelerometer-measured moderate-to-vigorous physical activity. ^a Data missing, n = 1 from perimenopausal group. ^b Data missing, n = 3 from premenopausal and n = 5 from perimenopausal and n = 6 from premenopausal and n = 6 from premenopausal group. ^c Data missing, n = 6 from premenopausal group. ^c Data missing, n = 6 from premenopausal and n = 6 from perimenopausal group. ^c Data missing, n = 6 from premenopausal group. ^c Data missing group group gr

Supplemental Table 2. Baseline anthropometrics and body composition results of the participants taking part either in the short-term, long-term or both follow-ups.

Not all participants took part in all of the anthropometrics and body composition measurements both at baseline and follow-up visit. The baseline population with a minimum of scale measured body mass consists of the following subpopulations:

- 49 participants, who were premenopausal at ERMA baseline and were re-measured only at long-term follow-up.
- 230 participants, who were perimenopausal at ERMA baseline and completed the short-term follow-up.
- 28 participants, who were perimenopausal at ERMA baseline and were re-measured only at long-term follow-up.

	All	Premenopausal	Perimenopausal
Dody mass Ira	(n = 307)	(n = 49)	(n = 258)
Body mass, kg	69.6 ± 10.9	68.7 ± 10.4	69.7 ± 11.0
Height, cm	165.3 ± 5.5	166.2 ± 5.1	165.1 ± 5.6
BMI, kg/m ²	25.5 ± 3.9	24.9 ± 3.6	25.6 ± 3.9
Underweight (<18.5)	0%	0%	0%
Normal weight (18.5–24.99)	51.8%	57.1%	50.8%
Overweight (25.0–29.99)	34.5%	34.7%	34.5%
<i>Obese (>30)</i>	13.7%	8.2%	14.7%
Total and regional fat ^a			
Total fat mass, kg	25.1 ± 8.7	22.8 ± 8.0	25.5 ± 8.8*
Total fat-%	35.1 ± 7.8	32.4 ± 7.6	35.6 ± 7.8**
Trunk fat mass, kg	12.8 ± 5.3	11.7 ± 4.8	13.0 ± 5.4
Gynoid fat mass, kg	4.9 ± 1.4	4.4 ± 1.4	5.0 ± 1.4*
Android fat mass, kg	2.2 ± 1.0	2.0 ± 0.9	2.3 ± 1.0
Right leg fat mass, kg	4.4 ± 1.5	3.9 ± 1.5	4.5 ± 1.5*
Gluteofemoral fat mass, kg	10.1 ± 3.4	9.1 ± 3.0	10.3 ± 3.4*
Gluteofemoral fat-%	36.0 ± 6.9	33.5 ± 6.8	36.4 ± 6.8**
Android-to-gynoid-ratio	0.45 ± 0.14	0.45 ± 0.16	0.45 ± 0.14

Values are presented as mean \pm SD. BMI, body mass index. ^a Data missing n=1 from premenopausal group and n=9 from perimenopausal group. ***p<0.001, **p<0.05 between menopausal groups